Position in RPRX
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$7,008,750
+$1,012,500 QoQ
Shares Held
125,000
0.0% QoQ
Ownership
0.022%
of shares outstanding
% of Portfolio
4.45%
of 13F equity value
Holder Rank
#184
of 644 holders
Holding Since
Dec 2023
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in RPRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CM Management, LLC holds $37,311,100 across 18 Biotechnology names. RPRX ranks #2 (18.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RIGL |
Rigel Pharmaceuticals Inc
|
250,000 | $9,780,000 | |
| 2 | RPRX |
Royalty Pharma plc
This page
|
125,000 | $7,008,750 | |
| 3 | CHRS |
Coherus Oncology, Inc.
|
2,100,000 | $2,940,000 | |
| 4 | COYA |
Coya Therapeutics, Inc.
|
400,000 | $2,340,000 | |
| 5 | ELDN |
Eledon Pharmaceuticals, Inc.
|
575,000 | $2,265,500 | |
| 6 | LTRN |
Lantern Pharma Inc.
|
500,000 | $2,085,000 | |
| 7 | IOVA |
Iovance Biotherapeutics, Inc.
|
450,000 | $1,872,000 | |
| 8 | AVIR |
Atea Pharmaceuticals, Inc.
|
355,000 | $1,650,750 |
All Filings in RPRX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,008,750 | 125,000 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $5,996,250 | 125,000 | Shares | Sole | 2026-05-08 | |
| 2025-12-31 | $2,898,000 | 75,000 | Shares | Sole | 2026-02-02 | |
| 2025-09-30 | $1,764,000 | 50,000 | Shares | Sole | 2025-11-13 | |
| 2024-12-31 | $4,081,600 | 160,000 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $4,526,400 | 160,000 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $4,219,200 | 160,000 | Shares | Sole | 2024-08-01 | |
| 2024-03-31 | $4,859,200 | 160,000 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $3,511,250 | 125,000 | Shares | Sole | 2024-02-12 | |
| No filing history on record for this holder in this stock. | ||||||